

Professor Maciej Banach, MD, PhD, FAHA, FESC, FNLA, FASA, FRSPH

ADDRESS FOR CORRESPONDENCE:

Department of Hypertension
Chair of Nephrology and Hypertension
Medical University of Lodz, Poland
WAM University Hospital in Lodz
Zeromskiego 113; 90-549 Lodz, POLAND
Phone No.: +48 42 639 37 71
Fax No.: +48 42 639 37 50
Mobile: +48 604 593 040
E-mail: maciejbanach@aol.co.uk

EDUCATION:

1996-2002	Medical University in Lodz graduated with distinction.
2003-2003	Postgraduate training in Ministry of the Interior Hospital n Lodz, Poland
2003-2006	Assistant in Department of Cardiac Surgery, 1 st Chair of Cardiology and Cardiac Surgery, Medical University in Lodz, Poland
2006	Doctor's degree (PhD) for the study titled: <i>"The comparison of selected hemodynamic parameters, and prognosis of patients subjected to aortic valve replacement, depending on the kind of defect and degree of heart failure"</i> .
2006-2008	Assistant Professor in Department of Cardiology, 1 st Chair of Cardiology and Cardiac Surgery, Medical University in Lodz, Poland
March 2008	Associate Professor in Department of Cardiology, 1 st Chair of Cardiology and Cardiac Surgery, Medical University in Lodz, Poland (Habilitation thesis entitled: <i>"Perioperative atrial fibrillation - predictors and prognosis"</i> , 28 th March 2008).
06.2008 - 03.2009	Head of the Department of Molecular Cardioneurology and Hypertension, Medical University of Lodz, Poland.
January 2009-	Associate Professor in Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland.
March 2009 -	Head of the Department of Hypertension, Medical University of Lodz, Poland.
April 2010 -	Professor at Medical University of Lodz, Poland.
10.2010 - 02.2012	Undersecretary of State (Deputy Minister) at Ministry of Science and Higher Education of Republic of Poland.
06.2012-	Head of Foreign Affairs Office at Medical University of Lodz, Poland.

SCIENTIFIC ACHIEVEMENTS:

1. Individual Study Course in Department of Allergology and Clinical Immunology, Medical University in Lodz, Poland (1998-2002).
2. Polish Ministry of Health Scholarship holder (1999-2002).
3. Author and co-author of over **350 manuscripts** from the field of Cardiology, Hypertension, Lipid Disorders, Cardiac Surgery, and Nephrology (including only full text manuscripts) and with **336 entries, 1815 citations and Hirsh's Index: 21** (according to *Google Scholar*), **194 entries, 1491 citations and Hirsh's Index: 20** (according to *SCOPUS Elsevier*) and **184 entries, 1091 citations Hirsh's Index: 18** (according to *Web of Science*).
4. Reviewer of grant applications in National Centre for Science (NCN), National Centre for Research and Development (NCRD) and Foundation for Polish Science (FPS) (2010-).
5. **Supervisor of 4 PhD theses (2 completed and 2 in process); Reviewer of 10 PhD theses.**
6. Author and co-author of **22 books (Author of 79 chapters)**: (1) *The role of trimetazidine in the treatment of heart diseases* (Termedia Publishing House, Poznan 2006); (2) *Metabolic syndrome - prevention and treatment* (Medycyna PLUS Publishing House, Warsaw 2006), (3) *Polish Risk Score of operating treatment of coronary heart disease (Polish Score)* (Medycyna PLUS Publishing House, Warsaw 2006), (4) *Current state of knowledge about statins* (Termedia Publishing House, Poznan 2008); (5) *Complications of the arterial hypertension* (Termedia Publishing House, Poznan 2007); (6) *Metabolic syndrome - prevention and treatment* (2nd Edition, Medical Academy Publishing House, Warsaw 2007), (7) *Complications following coronary angiography and angioplasty* (Termedia Publishing House, Poznan 2007); (8) *Complications of the arterial hypertension* (2nd Edition, Termedia Publishing House, Poznan 2009); (9) *Trimetazidine* (Termedia Publishing House, Poznan 2009); (10) *Simvastatin* (Via-Medica Publishing House, Gdansk 2009); (11) *Ezetimibe* (Via-Medica Publishing House, Gdansk 2010); (12) *Clinical Trials and Guidelines - Cardiology 2009* (Termedia Publishing House, Poznan 2010); (13) *Cardiology: Nebivolol* (Termedia Publishing House, Poznan 2010); (14) *Cardiology: Lisinopril* (Termedia Publishing House, Poznan 2010); (15) *Cardiology: Nebivolol* (Termedia Publishing House, 2nd Edition, Poznan 2010); (16) *Obesity and hypertension. Obesity and related comorbidities* (Polskie Towarzystwo Chorób Metabolicznych Lodz, Poland 2010); (17) *Cardiology: Irbesartan* (Termedia Publishing House, Poznan 2011); (18) *Ventricular Assist Devices* (Intech, USA, 2011); (19) *Practical Guidebook - how to use statins (Polish Editor)* (Termedia Publishing House, Poznan 2011); (20) *Arterial Hypertension Management 2012* (Cornetis Publishing House, Poland, 2012); (21) *Hypertension and Kidney. The management in hypertensive nephropathy* (Termedia Publishing House, Poznan 2012); (22) *Cardiology: Irbesartan* (2nd Edition, Termedia Publishing House, Poznan 2012).
7. Member of European Atherosclerotic Society (2012-), National Lipid Association (2010-), European Society of Hypertension (2010-), Heart Rhythm Society (2008-), American Heart Association (2007-), American Stroke Association (2007-), American Society of Angiology (2007-), Society of Geriatric Cardiology (US) (2008-), European Society of Cardiology (2005-), Working Group on Computers in Cardiology of ESC (WG15), Working Group on Cardiovascular Surgery of ESC (WG25),

Polish Society of Cardiology (2006-), Polish Society of Cardiac and Thoracic Surgeons (2004-), Heart Failure Association of the ESC (HFA) (2004-), European Heart Rhythm Association of ESC (EHRA) (2005-), Cardiothoracic Surgery Network (2004-), World Association of Medical Editors (WAME) (2005-) and Index Copernicus Scientists (2005-).

8. Head of Polish Lipid Association (PoLA) (2011-)

9. Head of regional (Lodz) chapter of Polish Society of Hypertension (2009-)

SELECTED PUBLICATIONS (SINCE 2006):

1. Piechowiak M, **Banach M**, Ruta J, Barylski M, Rysz J, Bartczak K, Markuszewski L, Zastlonka J, Goch JH. Risk factors of atrial fibrillation in adult patients in long-term observation following surgical closure of atrial septal defect type II. *Thorac Cardiovasc Surg* 2006; **54(4)**:259-263.
2. Kowalski J, Barylski M, **Banach M**, Grycewicz J, Irzmanski R, Pawlicki L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. *J Cardiovasc Pharm* 2006; **48(4)**: 143-147. **Times Cited: 21**
3. Rysz J, **Banach M**, Stolarek RA, Pasnik J, Ciałkowska-Rysz A, Baj Z. TNF-alfa priming effect on polymorphonuclear leukocytes reactive oxygen species generation and adhesion molecule expression in hemodialyzed patients. *Arch Immunol Ther Exp* 2006; **54(3)**:209-215.
4. **Banach M**, Rysz J, Drozd J, Misztal M, Barylski M, Okonski P, Irzmanski R, Zastlonka J. Risk factors of atrial fibrillation following coronary artery bypass grafting - preliminary report. *Circ J* 2006; **70(4)**: 438-441. **Times Cited: 35**
5. Rysz J, **Banach M**, Ciałkowska-Rysz A, Stolarek R, Drozd J, Okoński P. Blood serum levels of IL-2, IL-6, IL-8, TNF-a and IL-1b in patients on maintenance hemodialysis. *Cell Mol Immunol* 2006; **3(2)**:151-154. **Times Cited: 38**
6. Okoński P, **Banach M**, Rysz J, Irzmański R, Barylski M, Zastlonka J. L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury. *Ann Transplant* 2006; **11(1)**:26-32.
7. Rysz J, Potargowicz E, **Banach M**, Luczynska M, Stolarek RA, Bialasiewicz P, Kasielski M, Cialkowska-Rysz A, Nowak D. Increased whole blood chemiluminescence in patients with chronic renal failure independent of hemodialysis treatment. *Arch Immunol Ther Exp* 2006; **54(5)**: 347-355.
8. Rysz J., Stolarek RA, Majewska E, **Banach M**, Cialkowska-Rysz A, Baj Z. The increased levels of soluble TNFa receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis. *Am J Nephrol* 2006; **26**:437-444.
9. Kazmierski J, Kowman M, **Banach M**, Pawelczyk T, Okonski P, Iwaszkiewicz A, Zastlonka J, Sobow T, Kloszewska I. Preoperative predictors of delirium after cardiac surgery: a preliminary study. *Gen Hosp Psychiatry* 2006; **28(6)**: 536-538. **Times Cited: 40**
10. Piechota M, **Banach M**, Irzmański R, Misztal M, Rysz J, Barylski M, Piechota-Urbańska M, Kowalski J, Pawlicki L. N-terminal brain natriuretic propeptide levels correlate with

- procalcitonin and C-reactive protein levels in septic patients. *Cell Mol Biol Lett* 2007; **12(2)**:162-175.
11. Piechota M, **Banach M**, Irzmanski R, Barylski M, Piechota-Urbanska M, Kowalski J, Pawlicki L. Plasma endothelin-1 levels in septic patients. *J Intensive Care Med* 2007; **22(4)**:232-239. **Times Cited: 23**
 12. Irzmański R, **Banach M**, Piechota M, Kowalski J, Barylski M, Cierniewski Cz, Pawlicki L. Atrial, Brain Natriuretic Peptide and Endothelin-1 concentration in patients with idiopathic arterial hypertension. The dependence on the selected morphological parameters. *Clin Exp Hypertens* 2007; **29(3)**:149-64. **Times Cited: 18**
 13. **Banach M**, Goch A, Misztal M, Rysz J, Barylski M, Jaszewski R, Goch JH. Low output syndrome following aortic valve replacement. Predictors and prognosis. *Arch Med Sci* 2007; **3(2)**:117-122.
 14. Rysz J, **Banach M**, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M, Baj Z. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. *J Nephrol* 2007; **20**:444-452. **Times Cited: 24**
 15. Goch A, **Banach M**, Piotrowski G, Szadkowska, Goch JH. Echocardiographic evaluation of left atrium and left atrium appendage function in patients with atrial septum aneurysm - implications for thromboembolic complications. *Thorac Cardiovasc Surg* 2007; **55(6)**:365-370.
 16. Irzmanski R, Barylski M, **Banach M**, Piechota M, Kowalski J, Cierniewski C, Pawlicki L. The concentration of atrial and brain natriuretic peptide in patients with idiopathic arterial hypertension. *Med Sci Monit* 2007; **13(10)**:CR449-456.
 17. **Banach M**, Goch A, Okonski P, Misztal M, Rysz J, Zastónka J, Goch JH, Jaszewski J. Relation between postoperative mortality and atrial fibrillation before surgical revascularization - 3 years follow-up. *Thorac Cardiovasc Surg* 2008; **56(1)**:20-23.
 18. **Banach M**, Goch A, Misztal M, Rysz J, Jaszewski R, Goch JH. Predictors of paroxysmal atrial fibrillation In patients subjected to aortic valve replacement. *J Thorac Cardiovasc Surg* 2007; **134(6)**:1569-1576. **Times Cited: 19**
 19. Rysz J, Blaszczyk R, **Banach M**, Kedziora-Kornatowska K, Kornatowski T, Tanski W, Kedziora J. Evaluation of chosen parameters of antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation. *Arch Immunol Ther Exp* 2007; **55(5)**:335-340.
 20. Kazmierski J, Kowman M, **Banach M**, Fendler W, Okonski P, Banys A, Jaszewski R, Sobow T, Kloszewska I. The clinical utility and use of the DSM-IV and ICD-10 criteria, and the Memorial Delirium Assessment Scale in establishing diagnosis of delirium after cardiac surgery. *Psychosomatics* 2008; **49(1)**:73-76.
 21. Boncler M, Gresner P, Nocun M, Rywaniak J, Dolnik M, Rysz J, Wilk R, Czyz M, Markuszewski L, **Banach M**, Watala C. Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. *Biochem Biophys Acta* 2007; **1767(12)**:1651-1659.
 22. Kowalski J, **Banach M**, Barylski M, Irzmanski R, Pawlicki L. Carvedilol modifies antioxidant status of patients with stable angina. *Cell Mol Biol Lett* 2008; **12(2)**:230-239.
 23. **Banach M**, Misztal M, Goch A, Rysz J, Goch JH. Predictors of atrial fibrillation in patients

- following isolated surgical revascularization. A metaanalysis of 9 studies with 28 786 patients. *Arch Med Sci* 2007; **3(3)**: 229-239. **Times Cited: 21**
24. Piechota M, **Banach M**, Jacoń A, Rysz J. Natriuretic peptides and endothelins in cardiovascular diseases. *Cell Mol Biol Lett* 2008; **12(2)**:155-181. **Times Cited: 17**
 25. Reszka E, Jegier B, Wasowicz W, Lelonek M, **Banach M**, Jaszewski R. Detection of infectious agents by PCR in human aortic wall. *Cardiovasc Pathol* 2008; **17(5)**:297-302. **Times Cited: 22**
 26. **Banach M**, Mikhailidis DP, Ugurlucan M, Barylski M, Banyś A, Goch A, Goch JH. The significance of statin use in patients subjected to surgical coronary revascularization. *Arch Med Sci* 2007; **3(4A)**:S126-132.
 27. Alpagut U, Ugurlucan M, **Banach M**, Mikhailidis DP, Dayioglu E. Does the gender influence the patency of infrainguinal bypass grafts? *Angiology* 2008; **59**:278-282.
 28. Erer D, **Banach M**, Ugurlucan M. Endovascular treatment of mycotic aortic aneurysms. *J Thorac Cardiovasc Surg* 2008; **135**:1404.
 29. **Banach M**, Kazmierski J, Kowman M, et al. Atrial fibrillation as an independent predictor of delirium after cardiac surgery: A pilot study. *Med Sci Monit* 2008; **14(5)**:CR286-291.
 30. **Banach M**, Goch A, Mikhailidis DP, Rysz J, Rosano MCG. The role of trimetazidine after acute myocardial infarction. *Curr Vascul Pharmacol* 2008; **6(4)**:282-291.
 31. **Banach M**, Ugurlucan M, Mariscalco G, Rysz J, Goch JH. Statins in the prevention of postoperative atrial fibrillation. Is there really no effect? *Am Heart J* 2008; **155(6)**:e53.
 32. **Banach M**, Mariscalco G, Ugurlucan M, Rysz J. Carvedilol in the prevention of postoperative atrial fibrillation. What do we really know? *Circ J* 2008; **72**:1388.
 33. Mariscalco G, Sala A, **Banach M**, Cattaneo P. Dofetilide for the prevention of postoperative atrial fibrillation after coronary surgery: is a useful routine prophylaxis? *Am J Cardiol* 2008; **102**:506.
 34. Kowalczyk E, Kopff M, Kowalski J, Kopff A, Mikhailidis DP, Barylski M, **Banach M**. Effects of cardiovascular drugs on adenosine deaminase activity. *Angiology* 2008; **59(6)**:740-744.
 35. Selimoglu O, Ugurlucan M, Basaran M, Gungor F, **Banach M**, Cucu O, Ong LL, Gasparyan AY, Mikhailidis DP, Ogus TN. Efficacy of remote ischemic preconditioning on spinal cord protection against ischemic injury: Association with heat shock protein expression. *Folia Neuropathol* 2008; **46(3)**:204-212.
 36. **Banach M**, Goch JH, Ugurlucan M, Rysz J, Mikhailidis DP. Obesity and postoperative atrial fibrillation. Is there no connection? Comment on: Wanahita et al. "atrial fibrillation and obesity--results of a meta-analysis". *Am Heart J* 2008; **156(1)**:e5.
 37. Kocailik A, Basaran M, Ugurlucan M, Ozbek C, Kafali E, Yerebakan C, Selimoglu O, **Banach M**, Ucak A, Ogus TN, Us M. Papaverine solution improves preservation of saphenous vein grafts used during cardiac surgery. *Acta Cardiol* 2008; **63(4)**:445-9.
 38. **Banach M**, Mariscalco G, Ugurlucan M, Mikhailidis DP, Barylski M, Rysz J. The significance of preoperative atrial fibrillation (AF) in patients undergoing cardiac surgery. Preoperative atrial fibrillation - still underestimated opponent. *Europace* 2008; **10(11)**:1266-1270.

39. Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P, Cantore C, Biglioli P, Sala A. Atrial Fibrillation After Isolated Coronary Surgery Affects Late Survival. *Circulation* 2008; 118(16):1612-18. **Times Cited: 55**
40. Barylski M, Kowalczyk E, Banach M, Ciećwierz J, Pawlicki L, Kowalski J. Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. *Angiology* 2009; 60(1):87-92.
41. Goch A, Banach M, Mikhailidis DP, Goch JH. Endothelial dysfunction in patients with non-complicated and complicated hypertension. *Clin Exp Hypertens* 2009; 31(1):20-30. **Times Cited: 16**
42. Aydin U, Ugurlucan M, Gundor F, Banach M, et al. Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model. *Angiology* 2009; 60(3):370-77.
43. Ugurlucan M, Alpagut U, Banach M, Mikhailidis DP, Tireli E, Dayioglu E. Arteriovenous fistula leading to severe tortuosity and aneurysm formation. *J Cardiac Surg* 2009; 24(2):109.
44. Szadkowska I, Stanczyk A, Aronow WS, Kowalski J, Pawlicki P, Ahmed A, Banach M. Statin therapy in the elderly. *Arch Gerontol Geriatr* 2010; 50:114-118.
45. Kaminski KA, Kozieradzka A, Bonda T, Banach M, Kozuch M, Wojtkowska I, Dobrzycki S, Kralisz P, Nowak K, Prokopczuk P, Mikhailidis DP, Musial WJ. Percutaneous Coronary Interventions Affect Concentrations of Interleukin 6 and Its Soluble Receptors in Coronary Sinus Blood in Patients With Stable Angina. *Angiology* 2009; 60:322-8.
46. Goch A, Piotrowski G, Misiewicz P, Rysz J, Banach M. The clinical manifestation of myocardial infarction in elderly patients. *Clin Cardiol* 2009; 32:E45-E50.
47. Ugurlucan M, Erer D, Kalko Y, Gungor F, Haholu A, Basaran M, Banach M, Rysz J, Mikhailidis DP, Tireli E, Dayioglu E, Alpagut U. Aortic stiffness in diabetes mellitus--association with glutamine and heat shock protein 70 expression: a pilot study based on an experimental rodent model. *Expert Opin Ther Targets* 2009; 13(3):267-74.
48. Bielecka-Dabrowa A, Barylski M, Mikhailidis DP, Rysz J, Banach M. HSP 70 and atherosclerosis--protector or activator? *Expert Opin Ther Targets* 2009; 13(3):307-17. **Times Cited: 22**
49. Chrusciel P, Goch A, Banach M, Mikhailidis DP, Rysz J, Goch JH. Circadian changes in the haemostatic system in healthy men and patients with cardiovascular diseases. *Med Sci Monit* 2009; 15(10):RA203-208. **Times Cited: 17**
50. Rysz J, Aronow WS, Stolarek R, Hannam S, Mikhailidis DP, Banach M. Nephroprotective and clinical potential of statins in dialyzed patients. *Expert Opin Ther Targets* 2009; 13(5):541-50. **Times Cited: 19**
51. Gluba A, Banach M, Rysz J, Piotrowski G, Fendler W, Pietrucha T. Is polymorphism within eNOS gene associated with the late onset of myocardial infarction? A pilot study. *Angiology* 2009; 60(5):588-595.
52. Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. *Thyroid Res* 2009; 2(1):4.
53. Aronow WS, Banach M. Atrial Fibrillation: The New Epidemic of the Ageing World. *J Atrial Fibrillation* 2009; 1(6):337-361.

54. Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker W, Galanti A, Rysz J, Camm JA, White CM, Alfieri O. Postoperative Atrial Fibrillation - What we do really know? *Curr Vasc Pharmacol* 2010; **8(4)**:553-72.
55. Stepien M, Banach M, Mikhailidis DP, Gluba A, Kjeldsen SE, Rysz J. The role and the significance of statins in the treatment of hypertensive patients. *Curr Med Res Opin* 2009; **25**:1995-2005. **Times Cited: 19**
56. Gluba A, Banach M, Mikhailidis DP, Rysz J. Genetic determinants of cardiovascular disease. *In vivo* 2009; **23(5)**:797-812.
57. Piechota M, Barylski M, Hannam S, Mikhailidis DP, Rysz J, Banach M. Natriuretic Peptides in Septic Patients. *Curr Med Chem.* 2009; **16(30)**:4020-31.
58. Kozlowski D, Budrejko S, Lip GY, Rysz J, Mikhailidis DP, Raczak G, Banach M. Lone Atrial Fibrillation - What Do We Know? *Heart* 2010; **96(7)**:498-503.
59. Piffaretti G, Mariscalco G, Lomazzi C, Rivolta N, Riva F, Tozzi M, Carrafiello G, Bacuzzi A, Mangini M, Banach M, Castelli P. Predictive factors for endoleaks after thoracic aortic aneurysm endograft repair. *J Thorac Cardiovasc Surg.* 2009; **138(4)**: 880-885.
60. Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk - a pilot study. *Angiology* 2010; **61(2)**:157-65.
61. Szadkowska I, Pawlicki L, Kowalski J, Banach M, Goch JH, Chiziński K. Left ventricular dysfunction and NT-proBNP levels after first ST-elevation myocardial infarction treated with primary coronary angioplasty in patients with one-vessel disease. *Kardiol Pol* 2009; **67**:1201-1206.
62. Kozlowski D, Budrejko S, Lip GYH, Mikhailidis DP, Rysz J, Raczak G, Banach M. Vernakalant hydrochloride for the treatment of atrial fibrillation. *Expert Opin Investig Drugs* 2009; **18(12)**:1929-37.
63. Kowey PR, Dorian P, Mitchell B, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A Toft E, for the Atrial arrhythmia Conversion Trial (ACT-II) Investigators. Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation Following Cardiac Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial. *Circ Arrhythm Electrophysiol* 2009; **2(6)**:652-659. **Times Cited: 39**
64. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins. *Med Sci Monit* 2009; **15(12)**:MS1-5. **Times Cited: 26**
65. Rysz J, Banach M, Stolarek RA, Mikhailidis DP, Cialkowska-Rysz A, Pokoca L, Piechota M, Baj Z. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. *Int Urol Nephrol* 2011;**43(2)**:491-8
66. Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J. Ticagrelor - a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? *Med Sci Monit* 2009; **15(12)**:MS24-30.

67. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, **Banach M**. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. *Med Sci Monit* 2009; **15(12)**:MS12-23.
68. Bielecka-Dabrowa A, Mikhailidis DP, Hannam S, Rysz J, Michalska M, Akashi YJ, **Banach M**. Takotsubo cardiomyopathy - The current state of knowledge. *Int J Cardiol* 2010; **142(2)**:120-5. **Times Cited: 19**
69. **Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz S, Rysz J**. The role of Toll-Like Receptors in renal diseases. *Nat Rev Nephrol* 2010; **6(4)**:224-35. **Times Cited: 21**
70. Kazmierski J, Kowman M, **Banach M**, Fendler W, Okonski P, Banys A, Jaszewski R, Rysz J, Sobow T, Kloszewska I, for IPDACS Study. The use of DSM-IV and ICD-10 criteria and diagnostic scales for delirium among cardiac surgery patients: Results from IPDACS study. *J Neuropsychiatry Clin Neurosci* 2010; **22(4)**:426-32
71. **Desai RV, Banach M, Ahmed MI, et al**. Impact of Baseline Systolic Blood Pressure and Long-Term Outcomes in Patients with Advanced Chronic Systolic Heart Failure (Insights from the BEST Trial). *Am J Cardiol* 2010; **106(2)**: 221-227. **Times Cited: 14**
72. Bielecka-Dabrowa A, Goch JH, Rysz J, Maciejewski M, Desai R, Aronow WS, **Banach M**. Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study. *Lipids Health Dis* 2010; **9**:21.
73. Michalska M, Gluba A, Mikhailidis DP, Nowak P, Bielecka-Dabrowa A, Rysz J, **Banach M**. The role of polyphenols in cardiovascular disease. *Med Sci Monit* 2010; **16(5)**:RA110-9.
74. Vitale C, Banach M, Rosano GM. Heart Rate Control in an Unselected Consecutive Population of Outpatients With Stable Coronary Artery Disease : Analysis of the CARDIf Study Cohort. *Angiology* 2010; **61(8)**:763-7.
75. Mariscalco G, Braga SS, **Banach M**, Borsani P, Bruno VD, Napoleone M, Vitale C, Piffaretti G, Pedretti RF, Sala A. Preoperative n-3 Polyunsaturated Fatty Acids Are Associated With a Decrease in the Incidence of Early Atrial Fibrillation Following Cardiac Surgery. *Angiology* 2010; **61(7)**:643-50.
76. Piotrowski G, Gawor R, **Banach M**, Piotrowska A, Rysz J, Gawor Z. High sensitivity C-reactive protein, NT-proBNP and hemodynamic left ventricular function in acute coronary syndrome without ST segment elevation - a preliminary report. *Med Sci Monit*. 2010; **16(7)**:CR313-7.
77. Trynieszewski W, Gadzicki M, Rysz J, **Banach M**, Maziarz Z. The behaviour of bone mineral density and bone metabolism index in young and menopausal women with the consideration of body mass index. *Med Sci Monit*. 2010; **16(7)**:CR342-7.
78. Kowalczyk M, **Banach M**, Lip GYH, Kozłowski D, Mikhailidis DP, Rysz J. Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties. *Int J Clin Pract* 2010; **64(8)**:1148-1154.
79. **Banach M**, Casares FM, Kream RM, Gluba A, Rysz J, Stefano GB. Morphine-mediated alteration of hypertension-related gene expression in human white blood cells and multilineage progenitor cells. *J Hum Hypertens*. 2010 Nov;**24(11)**:713-20.

80. Kazmierski J, Kowman M, **Banach M**, Fendler W, Okonski P, Banys A, Jaszewski R, Rysz J, Mikhailidis DP, Sobow T, Kloszewska I; IPDACS Study. Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. *J Psychosom Res.* 2010;**69(2)**:179-85.
Times Cited: 24
81. Bielecka-Dabrowa A, Aronow WS, Rysz J, **Banach M**. Current place of beta-blockers in the treatment of hypertension. *Curr Vasc Pharmacol.* 2010 Nov;**8(6)**:733-41.
82. Stepień M, **Banach M**, Jankowski P, Rysz J. Clinical implications of non-invasive measurement of central aortic blood pressure. *Curr Vasc Pharmacol.* 2010 Nov;**8(6)**:747-52.
83. Mariscalco G, Lorusso R, Sessa F, Bruno VD, Piffaretti G, **Banach M**, Cattaneo P, Cozzi GP, Sala A. Imbalance between pro-angiogenic and anti-angiogenic factors in rheumatic and mixomatous mitral valves. *Int J Cardiol.* 2010;**152**:337-44.
84. **Banach M**, Kjeldsen SE, Narkiewicz K. Controversies in hypertension treatment. *Curr Vasc Pharmacol.* 2010 Nov;**8(6)**:731-2
85. Gluba A, **Banach M**, Rysz J. Are polymorphisms within endothelial nitric oxide synthase good predictors of coronary artery disease? *Cardiology.* 2010;**116(4)**:268-70
86. Waliszek-Iwanicka A, Waliszek M, **Banach M**, Rysz J, Gos R. Assessment of blood flow in posterior ciliary arteries and its correlation with intraocular and arterial blood pressures in patients with open angle glaucoma. *Med Sci Monit.* 2010 Oct 1;**16(10)**:CR501-9.
87. **Banach M**, Rysz J. Current problems in hypertension and nephrology. *Expert Opin Pharmacother.* 2010 Nov;**11(16)**:2575-8.
88. Gluba A, Rysz J, **Banach M**. Statins in patients with chronic kidney disease: why, who and when? *Expert Opin Pharmacother.* 2010 Nov;**11(16)**:2665-74.
89. **Banach M**, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, Guichard JL, Aban I, Love TE, Aronow WS, White W, Deedwania P, Fonarow G, Ahmed A. Relation of Baseline Systolic Blood Pressure and Long-Term Outcomes in Ambulatory Patients With Chronic Mild to Moderate Heart Failure. *Am J Cardiol* 2011; **107(8)**:1208-14.
90. Bielecka-Dabrowa A, Mikhailidis DP, Hannam S, Aronow WS, Rysz J, **Banach M**. Statins and dilated cardiomyopathy: do we have enough data? *Expert Opin Investig Drugs.* 2011;**20(3)**:315-23.
91. Bielecka-Dabrowa A, Aronow WS, Rysz J, **Banach M**. The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. *Curr Cardiovasc Risk Rep.* 2011;**5(2)**:174-179.
92. Bielecka-Dąbrowa A, Hannam S, Rysz J, **Banach M**. Malignancy-associated dyslipidemia. *Open Cardiovasc Med J.* 2011;**5**:35-40.
93. **Banach M**, Michalska M, Kjeldsen SE, Matyszko J, Mikhailidis DP, Rysz J. What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist? *Expert Opin Pharmacother.* 2011;**12**:1835-44
94. Barylski M, Mikhailidis DP, Ciebiada M, **Banach M**. Gender differences in the treatment of ischemic heart disease. *Curr Pharm Des.* 2011;**17(11)**:1059-69.

95. Tryniszewski W, Kuśmierczyk J, Maziarz Z, Goś R, Mikhailidis DP, **Banach M**, Rysz J, Pesudovs K. Correlation of the severity of diabetic retinopathy and the heart muscle perfusion in patients with type 2 diabetes. *J Diabetes Complications*. 2011;**25(4)**:253-7.
96. Akashi YJ, Ashikaga K, Takano M, Izumo M, Ishibashi Y, Kida K, Yoneyama K, Suzuki K, Miyake F, **Banach M**. Significance of 99mTc-Sestamibi myocardial scintigraphy after percutaneous coronary intervention in patients with acute myocardial infarction. *Med Sci Monit*. 2011;**17(3)**:CR140-5.
97. Meyer P, Desai RV, Mujib M, Feller MA, Adamopoulos C, **Banach M**, Lainscak M, Aban I, White M, Aronow WS, Deedwania P, Iskandrian AE, Ahmed A. Right ventricular ejection fraction <20% is an independent predictor of mortality but not of hospitalization in older systolic heart failure patients. *Int J Cardiol* 2012; **155**:120-5.
98. Bielecka-Dabrowa A, Rysz J, Mikhailidis DP, **Banach M**. What is the risk of hyperkalaemia in heart failure? *Expert Opin Pharmacother*. 2011; **12(15)**:2329-38.
99. Bielecka-Dabrowa A, Mikhailidis DP, Jones L, Rysz J, Aronow WS, **Banach M**. The meaning of hypokalemia in heart failure. *Int J Cardiol* 2011; (*in press*).
100. Kozłowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, **Banach M**. Dronedarone: An overview. *Ann Med*. 2012; **44(1)**:60-72.
101. **Banach M**, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients?: ACCF/AHA 2011 expert consensus document on hypertension in the elderly. *Pol Arch Med Wewn*. 2011;**121(7-8)**:253-8.
102. **Piotrowski G, Banach M, Gerdts E, Mikhailidis DP, Hannam S, Gawor R, Stasiak A, Rysz J, Gawor Z. Left atrial size in hypertension and stroke. J Hypertens. 2011;29(10):1988-93.**
103. Kowalczyk M, **Banach M**, Rysz J. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease. *J Nephrol*. 2011;**24(6)**:717-22.
104. Stepien M, Rosniak-Bak K, Paradowski M, Misztal M, Kujawski K, **Banach M**, Rysz J. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: Preliminary results. *Med Sci Monit*. 2011;**17(11)**:PR13-18.
105. Aronow WS, **Banach M**. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. *Blood Press*. 2012; **21(1)**:3-5.
106. Mariscalco G, Bruno VD, Cottini M, Borsani P, **Banach M**, Piffaretti G, Dominici C, Beghi C, Sala A. Optimal Timing of Discontinuation of Clopidogrel and Risk of Blood Transfusion After Coronary Surgery. *Circ J*. 2011; **75(12)**:2805-12.
107. Katsiki N, Mikhailidis DP, **Banach M**. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. *J Hypertens*. 2011;**29(12)**:2493-4.

108. Kowalczyk M, **Banach M**, Mikhailidis DP, Rysz J. Erythropoietin update 2011. *Med Sci Monit.* 2011;**17(11)**:RA240-247.
109. **Banach M**, Davidson M, Toth PP. Polish Lipid Association - a strong response to the problem of lipid disorders in Poland, Central and Eastern Europe. *J Clin Lipidol* 2012;**6(2)**:105-7.
110. Barylski M, Malyszko J, Rysz J, Mysliwiec M, **Banach M**. Lipids, blood pressure, kidney - what was new in 2011? *Arch Med Sci* 2011; **7(6)**:1055-1066.
111. Skora B, Gluba A, **Banach M**, Rozentryt P, Polonski L, Rysz J. Acute coronary syndromes in patients with chronic kidney disease. *Curr Vasc Pharmacol* 2012; (in press).
112. Alagiakrishnan K, **Banach M**, Jones LG, Ahmed A, Datta S, Aronow WS. Update on Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction in the Older Adults. *Ann Med* 2012; (in press).
113. Piechota M, Barylski M, Hannam S, Piechota-Urbanska M, **Banach M**. Rationale of statin therapy in septic patients. *Curr Vasc Pharmacol* 2012; (in press).
114. Gluba A, Mikhailidis DP, Lip GYH, Hannam S, Rysz J, **Banach M**. Metabolic syndrome and renal disease. *Int J Cardiol* 2012; (in press).
115. **Banach M**, Aronow WS. Hypertension therapy in the older adults---do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. *J Hum Hypertens* 2012; (in press).
116. **Mariscalco G, Cottini M, Zanobini M, Salis S, Dominici C, Banach M, Onorati F, Piffaretti G, Covaia G, Realini M, Beghi C. Preoperative Statin Therapy is not Associated with a Decrease in the Incidence of Delirium After Cardiac Surgery. Ann Thorac Surg 2012; (in press).**
117. Malyszko J, Malyszko JS, Mikhailidis DP, Rysz J, Zorawski M, Banach M. Hypertension and kidney disease: is renalase a new player or an innocent bystander? *J Hypertens.* 2012;**30(3)**:457-62.
118. Rizzo M, Montalto G, **Banach M**. The effects of statins on blood pressure: current knowledge and future perspectives. *Arch Med Sci* 2012; **8(1)**:1-3.
119. **Katsiki N, Banach M. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012; 172(11):895-6;**
120. **Gluba A, Bielecka A, Mikhailidis DP, Wong ND, Franklin SS, Rysz J, Banach M. An update on biomarkers of heart failure in hypertensive patients. J Hypertens. 2012 Sep;30(9):1681-9.**

121. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease? *Prog Lipid Res.* 2012 Oct;51(4):314-24.
122. Malyszko J, Malyszko JS, Rysz J, Mysliwiec M, Tesar V, Levin-Iaina N, Banach M. Renalase, Hypertension, and Kidney -- The Discussion Continues. *Angiology.* 2012; (in press).
123. Krasieńska B, Banach M, Karolczak-Kulesza M, Krasieński Z, Głuszek J, Tykarski A. Observations on degenerative changes within the optic nerve in patients with primary open glaucoma and arterial hypertension: 6-month follow-up. *J Clin Hypertens (Greenwich).* 2012 Oct;14(10):701-10
124. Rizzo M, Barylski M, Rizvi AA, Montalto G, Mikhailidis DP, Banach M. Combined Dyslipidemia: Should The Focus Be LDL Cholesterol or Atherogenic Dyslipidemia? *Curr Pharm Des.* 2012; (in press).
125. Banach M, Rizzo M, Obradović M, Montalto G, Rysz J, Mikhailidis DP, Isenović ER. PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders? *Curr Pharm Des.* 2012; (in press).
126. Kozłowski D, Budrejko S, Raczak G, Rysz J, Banach M. Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists. *Curr Pharm Des.* 2012; (in press).
127. Banach M, Malodobra-Mazur M, Gluba A, Katsiki N, Rysz J, Dobrzym A. Statin Therapy and New-Onset Diabetes: Molecular Mechanisms and Clinical Relevance. *Curr Pharm Des.* 2012; (in press).
128. Stepień M, Stepień A, Wlazel RN, Paradowski M, Rizzo M, Banach M, Rysz J. Predictors of Insulin Resistance in Patients With Obesity: A Pilot Study. *Angiology.* 2012; (in press).
129. Franczyk-Skóra B, Gluba A, Banach M, Kozłowski D, Matyszko J, Rysz J. Prevention of sudden cardiac death in patients with chronic kidney disease. *BMC Nephrol.* 2012;13:162.
130. Banach M, Aronow WS. Blood pressure j-curve: current concepts. *Curr Hypertens Rep.* 2012;14(6):556-66.
131. Anker MS, von Haehling S, Springer J, Banach M, Anker SD. Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. *Int J Cardiol.* 2013;162(2):73-6.

THE MOST RECENT LECTURES AND CONFERENCES' ACTIVITIES (2012-)

1. LECTURE: *What we should add to statin in order to decrease the residual risk and if LDL-C lowering below 70 mg/dL is safe and beneficial for patient?* (11th Feb. 2012) - Controversies in diabetes and cardiovascular, and kidney diseases, 11th February 2012, Warsaw, 2012
2. Member of the Scientific Committee - VI Congress TOP MEDICAL TRENDS, 23-25th March 2012, Poznan Poland
3. Chairman of the Session: Cardiology (23rd March 2012) - VI Congress TOP MEDICAL TRENDS, 23-25th March 2012, Poznan Poland
4. LECTURE: *Current recommendations of lipid disorders therapy* (23rd March 2012) - VI Congress TOP MEDICAL TRENDS, 23-25th March 2012, Poznan Poland
5. LECTURE: *New lipid fractions/biomarkers* (17th April 2012) - 24 hours with the most modern cardiology - VIII Conference of Cardiology Journal, 16-17th March 2012, Warsaw, Poland
6. Chairman of the Session: Cardiosexuology (13th April 2012) - 2nd International Congress - Woman and Man - Reproductive and Sexual Health, 13-14th April 2012, Warsaw, Poland
7. LECTURE: Hypercholesterolemia - the effect on reproductive and sexual health (13th April 2012) - 2nd International Congress - Woman and Man - Reproductive and Sexual Health, 13-14th April 2012, Warsaw, Poland
8. Chairperson - Parallel Oral Session 6C - OBESITY AND METABOLIC SYNDROME- (27th April 2012) - 22nd Scientific Meeting of the European Society of Hypertension (ESH), 26-29th April 2012, London, UK,
9. HONORARY INAUGURATING LECTURE: *Lipid disorders - current state of knowledge / Levels of scientific track* (18th May 2012) - The 7th International Scientific Conference of Medical Students and Young Doctors, 17-18th May, 2012, Katowice - Ligota, Poland
10. Head of the Organizing Committee - 2nd International Congress of Polish Lipid Association (PoLA), 7-8 September 2012, Warsaw, Poland
11. LECTURE: *The safety of statin therapy. Current state of knowledge (2012)* (07 Sept. 2012) - 2nd International Congress of Polish Lipid Association (PoLA), 7-8 September 2012, Warsaw, Poland
12. LECTURE: *New biomarkers in the diagnosis and therapy monitoring of lipid disorders - a chance for the effective fight against hyperlipidemia?* (07 Sept. 2012) - 2nd International Congress of Polish Lipid Association (PoLA), 7-8 September 2012, Warsaw, Poland
13. LECTURE: *Lipid disorders with the genetic basis - are we aware of the scale of the problem?* (07 Sept. 2012) - 2nd International Congress of Polish Lipid Association (PoLA), 7-8 September 2012, Warsaw, Poland
14. LECTURE: **Dysfunctional HDL - a novel important diagnostic and therapeutic target in cardiovascular disease? - (24.09.2012) - 10th European Federation for the Science and Technology of Lipids (Euro Fed Lipid) Congress, 23-26 September 2012, Cracow, Poland.**
15. Chairman of the Session: Original papers session - moderated posters - Arterial hypertension - from bench to bedside (20th Sept. 2012) - XVI International Congress of Polish Cardiac Society (PCS), 20-22 September 2012, Poznan, Poland.

16. **LECTURE: Experience in healthy ageing of Medical University of Lodz (09.10.2012) - *HEALTHY AGEING Acting for Innovation at Regional and Local level* - 9-10th October 2012, Brussels, Belgium**
17. **LECTURE: *Dyslipidaemia - what is better after 60 - higher or lower cholesterol?* (12th October 2012) - The 1st International Congress - Woman and Man - Healthy Aging, 12-13th October 2012, Warsaw, Poland**
18. **Chairman of the Session: Problematic patient with hypertension - how to plan therapy in different clinical situations in the optimal way (18th October 2012) - XIII Congress of Polish Society of Hypertension (PSH), 18-20 October 2012, Cracow, Poland**
19. **LECTURE: *Patient with hypertension and lipid disorders.* (18th October 2012) - XIII Congress of Polish Society of Hypertension (PSH), 18-20 October 2012, Cracow, Poland.**
20. **Member of the Scientific Committee - The World Congress of Clinical Lipidology, 6-8 December 2012, Budapest, Hungary**
21. **LECTURE: *High Density Lipoprotein (HDL)* (7th Dec. 2012) - The World Congress of Clinical Lipidology, 6-8 December 2012, Budapest, Hungary**
22. **Chairmen of Workshop 5 : *Statin Resistance/Intolerance* (8th Dec. 2012) - The World Congress of Clinical Lipidology, 6-8 December 2012, Budapest, Hungary**
23. **Member of the Scientific Committee - The 2nd International Conference on Prehypertension and Cardio Metabolic Syndrome, January 31 - 3rd February 2013, Barcelona, Spain.**
24. **LECTURE: *Statins and the Risk of Diabetes: Should We be Afraid of that?* (2nd Feb. 2013) - The 2nd International Conference on Prehypertension and Cardio Metabolic Syndrome, January 31 - 3rd February 2013, Barcelona, Spain.**
25. **Member of the Organizing Committee - 3rd International Conference on Clinical & Experimental Cardiology, 15-17th April, 2013 Chicago, USA**
26. **Member of the Scientific Committee - 2013 NLA Scientific Sessions, Las Vegas, NV, May 30-June 2, 2013.**
27. **LECTURE: *Statins and Blood Pressure* - 2013 NLA Scientific Sessions, Las Vegas, NV, May 30-June 2, 2013.**
28. **International Scientific Committee and Faculty Member - 10th International Congress on Coronary Artery Disease - from Prevention to intervention, October 13-16, 2013, Florence, Italy.**
29. **LECTURE: *What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?* - 10th International Congress on Coronary Artery Disease - from Prevention to intervention, October 13-16, 2013, Florence, Italy.**

EDITORIAL ACTIVITIES:

- 2005- Editor-in-chief of *Achieves of Medical Science* (AMS) (Termedia Publishing House, Poland): <http://www.archivesofmedicalscience.com>
- 2010- Editor-in-chief of *Cardiovascular Continuum* (CC) (International Science Literature, NY, USA): www.CardiovascularContinuum.eu

- 2008- Deputy Editor of *Thyroid Research* (TRJ) (www.thyroidresearchjournal.com) (BioMed Central, USA)
- 2006-2009 Managing Editor of *Central European Journal of Medicine* (CEJMed) (<http://www.springer.com/journal/11536>) (VERSITA, co-published with Springer Verlag, Germany)
- 2010- Deputy Editor of *Clinical and Experimental Medical Letters* (CEML) (International Science Literature Ltd, NY, USA): www.ceml-online.com
- 2005-2009 Executive Editor of *Clinical and Experimental Medical Letters* (CEML) (<http://www.ceml.com.pl>) (Akademia Medycyny Publishing House, Poland)
- 2010- Associate Editor of *Recent Patents on Cardiovascular Drugs Discovery* (Bentham Science, USA)
- 2006- Associate Editor of *Polish Journal of Cardio-Thoracic Surgery* (Termedia Publishing House, Poland)
- 2010- Section Editor in Hypertension of *Evidence Based Cardiology* (Termedia Publishing House, Poland):
http://www.termedia.pl/Czasopismo/Kardiologia_Oparta_na_Faktach-62
- 2005- Section Editor of *Pharmacy in Practice* (Akademia Medycyny Publishing House, Poland) and *OPM* journal (ELAMED Publishing House, Poland)
- 2008- Senior Editor of *Neuroscience Imaging* (Nova Science Publishers, USA) (https://www.novapublishers.com/catalog/editorial.php?products_id=1686)
- 2008- Section Editor in Cardiology of *The Open Atherosclerosis & Thrombosis Journal* (Bentham Science Publishers Ltd, USA) (<http://www.bentham.org/open/toathertj/EBM.htm>)
- 2009- Scientific Coordinator of *Central European Journal of Urology* (CEJUrol) (Polish Society of Urology Publishing House, Poland)
- 2009-2010 Scientific Coordinator of *Polish Journal of Surgery* (Polish Society of Surgery, Lodz, Poland).
- 2010- Guest Editor of the special issues in *Current Vascular Pharmacology* (2010 and 2013); *Expert Opinion in Pharmacotherapy* (2010) and *Current Hypertension Reports* (2013).

RECENT CLINIAL TRIALS (SINCE 2005):

- 2003-2007 ***Polish Score of Risk (PSR) of surgery of patients with ischemic heart disease.*** 12-centre study founded by Polish Ministry of Health (KBN, No. 3 P05C 020 25) (Co-*Investigator*) (Level of financing: 150.000 EURO)
- 2005- ***IPDACS (Incidence and Predictors of Delirium After Cardiac Surgery) Trial*** (Study NCT00784576). One-centre study to the point of predictors of postoperative delirium (Co-*Investigator and Study Coordinator*). Medical University of Lodz (Poland)/Polish Ministry of Science and Higher Education (Level of financing: 20.000 EURO)

- 2005-2007 **ACT 2 Trial** to the point of new antiarrhythmic intravenous preparation (RSD1235 - Vernakalant) in the treatment of atrial fibrillation/atrial flutter following coronary artery bypass graft (CABG) or valve replacement surgery. Founded by CARDIOME (Vancouver, B.C., Canada) (*Principal Local Investigator*). (Level of financing: >100.000 EURO per centre)
- 2008-2012 **SWEEP TRIAL** to the point of the application of percutaneous erythropoietin in dialysis and pre-dialysis patients with chronic renal failure. Founded by HEXAL (USA) (*Principal Local Investigator*). (Level of financing: >80.000 EURO per centre)
- 2007-2010 ***The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle in patients with dilated cardiomyopathy*** (ClinicalTrial No.: NCT01015144) (*Study Director*) Medical University of Lodz (Poland) (Level of financing: 20.000 EURO)
- 2009-2012 Follow up of **SWEEP TRIAL** to the point of the application of percutaneous erythropoietin in dialysis and pre-dialysis patients with chronic renal failure. Founded by HEXAL (USA) (*Principal Local Investigator*). The study has been preliminary finished.
- 2009- Simvastatin in the Treatment of Isolated arterial hypertension and Prevention of cardiovascular Events - **STIPPARE Trial** (ClinicalTrial No.: NCT01017835) (*Principal Investigator*); Medical University of Lodz (Poland)/Polish Ministry of Science and Higher Education (Level of financing: >40.000 EURO)
- 2010- **FER-CKD Trial** (An open-label multicentre, randomised 3-arm study to investigate the comparative efficacy and safety of intravenous ferric carboxymaltose versus oral iron for the treatment of iron deficiency anaemia in subjects with non-dialysis-dependent chronic kidney disease) (*Co-Investigator*) *Founded by* Vifor Pharma/ICON (*Co-Investigator*) (Level of financing: >300.000 EURO per centre)
- 2010-2011 ***The role of atorvastatin on inflammatory and left ventricle parameters in patients with dilated cardiomyopathy - three year follow-up*** (IUVENTUS PLUS 2010 Research grant - IP2010002770; Polish Ministry of Science and Higher Education; *Study Coordinator*); (Level of financing: 20.000 EURO)
- 2011- ***The role of atorvastatin on adipokine profile secretion in patients with hypertension (Prodiabetic role of statins)*** - Medical University of Lodz/ Polish Ministry of Science and Higher Education Research Grant for Young Investigators (No. 502-03/5-139-01/502-54-057) (*Principal Investigator*) (Level of financing: 10.000 EURO)
- 2011-2012 ***The analysis of the level of knowledge and awareness of population of Lodz about the subject of hypertension and its complications.*** Medical University of Lodz/ Polish Ministry of Science and Higher Education Research Grant for Young Investigators (No. 502-03/5-139-02/502-54-063) (*Principal Investigator*) (Level of financing: 7.000 EURO)
- 2011-2012 ***The evaluation of heart failure therapy depending on the heart architecture analysis and its global function in the echocardiography, as well as patients'***

- genetic profile.*** Medical University of Lodz/ Polish Ministry of Science and Higher Education Research Grant for Young Investigators. (No. 502-03/5-139-02/502-54-008) (*Study Coordinator*) (Level of financing: 20.000 EURO)
- 2012- ***The influence of atorvastatin on inflammation parameters and left ventricle function in patients with dilated cardiomyopathy and heart failure with different etiology - analysis of new heart failure biomarkers.*** (IUVENTUS PLUS 2010 Research grant - IP2011003271; Polish Ministry of Science and Higher Education; *Study Coordinator*); (Level of financing: 25.000 EURO)
- 2012- ***Seeking for the new early predictors of left ventricle dysfunction in patients with hypertension.*** (Polish Cardiac Society grant for Young Investigators) (*Study Coordinator*); (Level of financing: 22.000 EURO)
- 2013- ***Healthy Ageing Research Centre (HARC)*** (7 th Framework Programme for Research - FP7-REGPOT-2012-2013-1; No. 316300) (Investigator, Member of the Steering Committee) (Level of financing: 4,945,664 EURO)

SUBMITTED GRANT PROPOSALS:

- COST Action - Biomedicine and Molecular Biosciences (BMBS) - ***European Network on the Metabolic Syndrome (EurNetMetS)*** (oc-2012-1-12526) (*Head of Working Group 1 - Clinical Trials*) (status: resubmission by March 2013) (level of financing - max. 520,000 Euro)
- COST Action - Biomedicine and Molecular Biosciences (BMBS) - ***The European Network on Hypertension and Arterial Research (EU-HyperNet)*** (oc-2012-2-13829) (Status: resubmission by March 2013) (*Principal Investigator/Grant Holder*) (level of financing - max. 520,000 Euro)
- FP7 HEALTH.2013.4.2-2: Adverse drug reaction research - Proposal: ***GENETIC RESEARCH FOR PREVENTION OF ADVERSE DRUG ASSOCIATED REACTIONS: REACTIONS TO ANTIHYPERTENSIVE AND LIPID LOWERING TREATMENTS (SHOT-GRADAR)*** (*Member of the Executive Committee, National Co-Coordinator of follow up in Polish patients*) (status: proposal submitted) (level of financing - up to 6,000,000 Euro)
- FP7 HEALTH.2013.2.4.2-2: Comparative effectiveness research of existing technologies for prevention, diagnosis and treatment of cardiovascular diseases - Proposal: ***MONITORING ORGAN DAMAGE AND ARTERIAL PRESSURES IN GUIDING THERAPY TO PREVENT OUTCOMES IN HIGH RISK HYPERTENSION (SHOT-MODAP)*** (*Member of the Executive Committee, National Co-Coordinator of blood pressure and organ damage measurement technologies in Polish patients, Coordinator of relations with Health Authorities*) (status: proposal submitted) (level of financing - up to 6,000,000 Euro)

- Marie Curie Initial Training Networks (ITN) - FP7-PEOPLE-2013-ITN: *CheMeD - From ChemLab to Molecular Diagnostics* (Supervisor, Member of the Executive Committee) (status: proposal submitted) (level of financing - >2,000,000 Euro)
- National Centre for Science - OPUS-4 program – *The influence of renal denervation on pathomechanisms of targeted organs damage in the course of arterial hypertension* (Member of the Executive Committee) (status: proposal submitted) (level of financing - 1,000,000 PLN)

EDITORIAL BOARD MEMBERSHIP:

Polish Geriatrics (2005-)

Folia Hepatologica (2006-)

Orvosi Hetilap (2006-)

Geriatrics (Warsaw) (2007-)

Scientific Journals International (2007-)

The Open Cardiovascular Medicine Journal (2007-)

Angiology (2008-)

Journal of Atrial Fibrillation (2008-)

Acta Medica (2008-)

American Journal of Biomedical Sciences (2009-)

Current Drug Therapy (2009-)

Journal of Community Medicine (2009-)

International Journal of Hypertension (2009-)

Medical Review (Bulgaria) (2009-)

Recent Patents on Cardiovascular Drugs Discovery (2009-)

Open Journal of Cardiology (2009-)

Polish Journal of Palliative Medicine (2009-)

Expert Opinion on Pharmacotherapy (2009-)

Medical Science Monitor (2010-)

Hellenic Journal of Atherosclerosis (2010-)

International Journal of Occupational Medicine and Environmental Health (2010-)

International Journal of Pharmacology (2011-)

Journal of Hypertension - Open Access (2011-)

World Journal of Medicine and Medical Science (2013-)

JOURNALS' REVIEWER:

Vascular Health and Risk Management (2012-)

Expert Opinion On Emerging Drugs (2012-)

BMC Medicine (2012-)
PLOS One (2012-)
Circulation: Arrhythmia and Electrophysiology (2012-)
Heart and Vessels (2012-)
Journal of the Renin-Angiotensin-Aldosterone System (2012-)
Therapeutic Advances in Cardiovascular Disease (2012-)
Recent Patents on Cardiovascular Drug Discovery (2012-)
Hypertension Research (2012-)
European Heart Journal (2011-)
European Journal of Internal Medicine (2011-)
Journal of Cardiovascular Surgery (2011-)
Future Cardiology (2011-)
Current Medical Research and Opinion (2011-)
Recent Patents on Biomedical Engineering (2011-)
Expert Review of Cardiovascular Therapy (2011-)
American Journal of Hypertension (2011-)
Journal of Clinical Hypertension (2011-)
Atherosclerosis (2010-)
Drugs (2010-)
BMC Cardiovascular Disorders (2010-)
Expert Opinion On Emerging Drugs (2010-)
Expert Opinion on Pharmacotherapy (2010-)
American Journal of Men's Health (2010-)
Polish Archives of Internal Medicine (2010-)
International Urology and Nephrology (2010-)
Heart (2009-)
Life Sciences (2009-)
Journal of the American College of Cardiology (2009-)
International Journal of Hypertension (2009-)
Biomarkers in Medicine (2009-)
Aging Health (2009-)
Current Drug Therapy (2009-)
Open Clinical Chemistry Journal (2009-)
Journal of Human Hypertension (2009-)
American Journal of Cardiology (2009-)
Clinical and Experimental Pharmacology and Physiology (2009-)
American Journal of Cardiovascular Drugs (2009-)
Archives of Medical Research (2009-)
Lipids (2008-)
Heart Rhythm (2008-)

Current Pharmaceutical Design (2008-)
 Clinics (Sao Paolo, Brazil) (2008-)
 Clinical Cardiology (2008-)
 Geriatrics (Warsaw) (2008-)
 Kardiologia Polska (2008-)
 Expert Opinion on Pharmacotherapy (2007-)
 Nephrology (2007-)
International Journal of Cardiology (2007-)
 Cell Biology International (2007-)
 Journal of Diabetes and Its Complications (2007-)
 Molecular and Cellular Biochemistry (2007-)
 Geriatrics (2007-)
 Scientific Journals International (2006-)
 Yonsei Medical Journal (2006-)
 Pharmacy in Practice (2006-)
 British Journal of Anaesthesia (2006-)
 Kidney International (2006-)
 Archives of Medical Science (2005-)
 Clinical and Experimental Medical Letters (2005-)
 Polish Geriatrics (2005-)
 Medical Science Monitor (2005-)
 Pharmaceutical Research (2004-)

OTHER ACHIEVEMENTS:

2012- Member for the National Coalition for Healthy Aging
 2012 Super-Talent in Medicine 2012 - the winner of the competition for young scientists in medicine (up to 40) founded by Puls Medycyny.
 2012 Fellow of National Lipid Association (FNLA)
 2012 **Vice-Chairman of the Supervisory Board of Technopark Lodz (Lodz, Poland)**
 (<http://www.technopark.lodz.pl/en>)
 2011 **Member of the Working Core of Biomedical Research in Europe/European Council for Health Research (in European Commission)**
 2010-2012 **Member of the Steering Committee of European Innovation Partnership - Active and Healthy Aging (EIP-AHA)**
 2011 The Scientific Award from Ministry of Health in Poland for the cycle of publications on *Diagnosis and Management in Hypertension*.
 2011 Fellow of American Heart Association - Council for High Blood Pressure Research (FAHA)

- 2011 Fellow of Royal Society for Public Health (FRSPH)
- 2009-2012 The Scientific Awards from the President of Medical University of Lodz for the scientific achievements.
- 2010 The member of Advisory Committee of Young Scientists at Polish Ministry of Science and Higher Education.
- 2009 The Scientific Award from Ministry of Health in Poland for the cycle of manuscripts on “*Postoperative atrial fibrillation in patients subjected to surgical revascularization*”.
- 2009 Winner for the best original manuscript published in *Kardiologia po Dyplomie* in 2008.
- 2009 Member of Board Committee of Polish Ministry of Science and Higher Education on the evaluation of projects in the Program of Innovative Economy (POIG.01.01.02)
- 2008 Fellow of Society of Geriatric Cardiology (FSGC)
- 2008 Fellow of European Society of Cardiology (FESC)
- 2008 Winner of the Stipend for Young Researches of Foundation for Polish Science (FNP)
- 2007 Fellow of American Society of Angiology (FASA)
- 2007 Winner of the Travel Grant of the Heart Failure Association
- 2007 Winner of the Travel Grant of the European Society of Hypertension
- 2007 Winner of the Conference Grant of the Foundation for Polish Science (FNP) (www.fnp.org.pl)
- 2007 1st place in annual scientific ranking of Medical University of Lodz, Poland for year 2006 in category - the total number of full-text manuscripts (63).
- 2006 Winner of 6TH Edition of Politics Journal’s program for the Best Young Scientist in Poland
- 2006- Scientific Coordinator of Termedia Publishing House, Poznan, Poland
- 2006 6th place in annual scientific ranking of Medical University of Lodz, Poland for year 2005 in category - total number of full-text manuscripts (62).
- 2005 Winner of the Travel Grant of the Heart Failure Association
- 2005 Winner of the Conference Grant of the Foundation for Polish Science (FNP) (www.fnp.org.pl)
- 2005 2nd place in annual scientific ranking of Medical University of Lodz, Poland for year 2004 in category - number of publications with Index Copernicus Score (40), and 10th place in the total number of published manuscripts for year 2004 (54).
- 2002-2008 Vice-president of Young Doctor Club at District Health Chamber in Lodz (RMC), Poland.